Whats New
Rivaroxaban receives draft NICE Guidance
National Institute for Health and Clinical Excellence issues draft guidance on Rivaroxaban the first once a day new oral anticoagulant for use in non-valvular atrial fibrillation
Posted in: Whats New
First new oral-anticoagulant in nearly 60 years, for stroke prevention in atrial fibrillation receives final guidance
The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending the new oral anticoagulant, Pradaxa® (dabigatran etexilate) as an option for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (AF) and one or more risk factors. This decision means dabigatran must now be made available for use by the NHS and that patients have the right to receive it if clinicians deem it clinically appropriate.
Posted in: Whats New
New report unveils worrying truth that patients with AF are unaware of stroke risk - Leading charities call for change in the management of life-threatening condition
A new report launched by AntiCoagulation Europe (ACE) highlights that over half of UK patients diagnosed with AF are not aware of the condition’s life-threatening link to stroke. It also reveals that over half of these UK patients believe that their lives are more affected by their warfarin therapy to reduce risk of stroke than the condition itself.
Posted in: Whats New
Rivaroxaban receives licence in the UK
Rivaroxaban (Xarelto) receives licence in the UK for prevention of stroke in atrial fibrillation and the treatment of deep vein thrombosis and pulmonary embolism
Posted in: Whats New
First New Anticoagulant In Over 50 Years Licenced For Stroke Prevention In Atrial Fibrillation
4th August 2011 Boehringer Ingelheim announce that Pradaxa (Dabigatran Etexilate) has received its licence for use in stroke prevention in Atrial Fibrillation. The National Institute for Clinical Excellence is expected to issue guidance later this year.
Posted in: Whats New
Apixiban (ELIQUIS®) has been granted a licence in the UK for the Prevention of Blood Clots after Elective Hip or Knee Replacement
“Blood clots are responsible for around 25,000 preventable deaths in the UK annually and preventing them following, for example, major joint surgery, is a priority for the NHS. Apixaban represents a new option in clot prevention for UK surgeons," said Dr Ander Cohen, Honorary Consultant Vascular Physician at King's College Hospital, London.
Posted in: Whats New
Einstein - Extension study
Results from the EINSTEIN-Extension study, demonstrate that the factor Xa inhibitor rivaroxaban (Xarelto), when compared to placebo, significantly reduced the risk of a recurrent symptomatic venous thromboembolism (VTE).
Posted in: Whats New
RE-COVER Study
New anticoagulant drug dabigatran is a safe effective alternative to warfarin for the treatment of Venous thromboembolism Venous thromboembolism is the umbrella term for deep vein thrombosis (blood clots in the legs and pulmonary embolism (blood clots in the lungs.
Posted in: Whats New
New anticoagulants - latest news
In September 2010 the U.S. Food and Drugs Administration (FDA) Advisory Committee has recommended dabigatran etexilate (Pradaxa) for use in stroke prevention for patients with non-valvular atrial fibrillation (AF).
Posted in: Whats New